This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

27 Sep 2013

Merck Update on Combination Medicine JUVISYNC (Sitagliptin and Simvastatin) Tablets

Merck, known as MSD outside the US and Canada, has said that the company will voluntarily discontinue distributing JUVISYNC (sitagliptin and simvastatin) tablets to pharmacies and wholesalers in the US and Puerto Rico.

This decision is for business reasons only and is not due to the efficacy or safety profile of JUVISYNC or the individual components. JUVISYNC is a treatment that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication simvastatin. Sitagliptin and simvastatin will continue to be available as separate medicines.


JUVICOR, the brand name of the sitagliptin/simvastatin combination tablet outside the US, will continue to be marketed and distributed outside the US. JUVICOR is currently approved in 10 countries, and Merck plans to continue filing applications in additional countries.

Related News